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ABSTRACT
Objective: To examine whether preadmission
glucocorticoid use increases the risk of anastomotic
leakage after colon and rectal cancer resections.
Design: A population-based cohort study.
Setting: Denmark (2001–2011).
Participants: We identified patients who had
undergone a primary anastomosis after a colorectal
cancer resection by linking medical registries.
Participants who filled their most recent glucocorticoid
prescription ≤90, 91–365 and >365 days before their
surgery date were categorised as current, recent and
former users, respectively.
Main outcome measures: We calculated 30-day
absolute risk of anastomotic leakage and computed
ORs using logistic regression models with adjustment
for potential confounders.
Results: Of the 18 190 patients with colon cancer,
anastomotic leakage occurred in 1184 (6.5%).
Glucocorticoid use overall was not associated with an
increased risk of leakage (6.4% vs 6.9% among never-
users; OR 1.05; 95% CI 0.89 to 1.23). Categories of
oral, inhaled or intestinal-acting glucocorticoids did not
greatly affect risk of leakage. Anastomotic leakage
occurred in 695 (13.2%) of 5284 patients with rectal
cancer. Glucocorticoid use overall slightly increased
risk of leakage (14.6% vs 12.8% among never-users;
OR 1.36, 95% CI 1.08 to 1.72). Results did not differ
significantly within glucocorticoid categories.
Conclusions: Preadmission glucocorticoids modestly
increased the risk of anastomotic leakage mainly after
rectal cancer resection. However, absolute risk
differences were small and the clinical impact of
glucocorticoid use may therefore be limited.
INTRODUCTION
Anastomotic leakage is a serious complica-
tion after colorectal cancer (CRC) resection,
and inevitably increases morbidity, mortality
and hospital resource utilisation.1 2
Moreover, leakage may negatively affect the
risk of local cancer recurrence and long-term
survival.3
Synthetic glucocorticoids are potent
immunosuppressive drugs that are widely
used to treat various chronic inflammatory
diseases and some malignancies.4 Although
glucocorticoids have been associated with
impaired wound healing in skin,5 6 their
effect on colon and rectal anastomoses is
controversial.7–18 Some animal studies of
intestinal anastomoses have demonstrated
that glucocorticoids impair healing and
reduce the tensile strength of wounds,7–9
while others have not.10 11 Clinical data are
also mixed. Several reports have indicated
that glucocorticoid use might predispose to
leakage,12–15 although others have not.16–18
Unfortunately, existing studies were limited
by sparse data (including 0–4 exposed
cases),12–18 and by the consideration of
colon and rectal surgery together rather
than separately.12–14 17 It is important to
Strengths and limitations of this study
▪ The study included all Danish patients with colon
and rectal cancer who had a primary anasto-
mosis after a colorectal cancer resection during
the study period. The study had complete
follow-up on all participants.
▪ Using electronic registries, we had accurate data
on glucocorticoid prescriptions.
▪ Because there were no clear standards for the
recording of anastomotic leakage during the
study period, completeness and validity in the
registries may be imperfect.
▪ The completeness of the Danish National
Registry of Patients may vary for different dis-
eases, and we cannot exclude the possibility that
confounding by indication influenced our results
although we adjusted for comorbidity in multi-
variate models.
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distinguish between colon and rectal procedures,
because the anatomy and surgical techniques differ,
leading to substantial differences in leakage rates: 3–4%
after colonic surgery compared with 11–12% after rectal
surgery.19
On the basis of available evidence, surgeons may ques-
tion the safety of primary anastomoses in glucocorticoid
users. To address the limitations of earlier studies, we
examined associations between glucocorticoid adminis-
tration and the risk of anastomotic leakage, in a large




We conducted a cohort study in the setting of the entire
Danish population, comprising approximately 6.5
million individuals cumulatively over the study period.
The Danish National Health Care provides free access to
tax-supported health services for all residents and
refunds a part of patient costs for most prescribed drugs.
Health service utilisation is registered to individual
patients by use of the personal identification number
assigned to each Danish citizen at birth and to residents
on immigration. The use of this system facilitates unam-
biguous individual-level linkage of nationwide
registries.20
Patients with colon and rectal cancer
We identified all 23 474 residents of Denmark who had
a colonic or rectal cancer resection and primary anasto-
mosis between 1 May 2001 and 31 December 2011, and
who were reported in the database of the Danish
Colorectal Cancer Group21 (figure 1). Beginning in
2001, this clinical database has registered all patients
with an incident colon or rectal adenocarcinoma, the
latter defined as those located 15 cm or less from the
anus, diagnosed or treated in surgical departments in
Denmark.21 Completeness of cancer registration (ie, the
proportion of those registered in the database out of
those registered in Danish National Registry of Patients)
in the database was 98–100% during 2001–2010.22 Data
regarding patient, tumour and treatment characteristics,
as well as postoperative outcomes including anastomotic
leakage (arbitrarily defined as those occurring within
30 days postoperatively), are collected by the Danish
Colorectal Cancer Group using standardised forms that
are completed by the treating physicians.21 We retrieved
data regarding preoperative American Society of
Anesthesiologists’ Physical Status Classification (ASA)
score,23 cancer site, tumour extent, node involvement
and distant metastases allowing for staging (recorded as
localised or non-localised if the cancer involved nodes
or distant organs)24 as well as date of surgery, surgical
urgency (planned or acute), approach (laparoscopy or
laparotomy), procedure (type of resection), periopera-
tive blood transfusion and postoperative anastomotic
leakage. Finally, we obtained information regarding
smoking status, which is recorded from patient question-
naires collected by the Danish Colorectal Cancer Group
until 2009, and thereafter by the treating physicians.
Use of glucocorticoids
The Danish National Registry of Medicinal Products has
automatically recorded prescriptions dispensed at
Danish pharmacies with complete coverage since 1995.25
Each record logs information about the type and quan-
tity of medication dispensed according to the Anatomical
Therapeutic Chemical (ATC) Classification System and the
prescription redemption date. We used this registry to
identify all prescriptions of oral, inhaled and
intestinal-acting glucocorticoids redeemed before the
Figure 1 Flow chart illustrating
exclusions of patients with
colorectal cancer recorded in the
Danish Colorectal Cancer
Database (DCCD), 2001–2011.
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CRC surgery date (see online supplementary table S1
for ATC codes). Intestinal-acting glucocorticoids
included rectally administered formulas as well as cap-
sules that release active substances into the ileum or
proximal colon. On the basis of methods used previ-
ously,26 we categorised exposure into the following five
main groups: (1) lack of use (‘never-use’), (2) oral
glucocorticoid use only, (3) inhaled glucocorticoid use
only, (4) intestinal-acting glucocorticoid use only and
(5) mixed use (ie, treatment with glucocorticoids from
at least two of the previous three groups). We further
categorised oral and inhaled glucocorticoid use accord-
ing to the timing of use as: current use (most recent pre-
scription filled within 90 days before the surgery date),
recent use (most recent prescription filled within 91–
365 days before the surgery date) and former use (most
recent prescription filled more than 365 days before the
surgery date). Intestinal-acting glucocorticoid use was
not divided into subcategories owing to the paucity of
individuals in that group.
Comorbidity and medication
The Danish National Registry of Patients has tracked all
non-psychiatric hospitalisations since 1977, and out-
patient visits since 1995, including essentially all specialist
care in the country.27 Recorded information includes
dates of admission and discharge, surgical and diagnostic
procedures, and discharge diagnoses coded by physi-
cians according to the 8th revision of the International
Classification of Diseases (ICD-8) until the end of 1993 and
the 10th revision (ICD-10) since then. Using records
from the Danish National Registry of Patients and the
Charlson Comorbidity Index (CCI), we summarised
each patient’s medical history from 1977 until the
surgery date, excluding colon or rectal cancer diagnosis
(see online supplementary table S2 for ICD codes defin-
ing a modified CCI).28 The CCI assigns between 1 and 6
points to a range of diseases, which are then summed to
obtain an aggregate score. We grouped patients accord-
ing to their CCI score: 0 (low comorbidity), 1–2 (moder-
ate comorbidity) and 3+ (severe comorbidity). In
addition, we obtained recorded diagnoses of inflamma-
tory bowel disease, autoimmune disease, alcoholism and
obesity, because these diagnoses are not included in the
CCI (see online supplementary table S3 for ICD codes).
Using the Danish National Registry of Medicinal
Products, we also identified filled prescriptions of non-
steroidal anti-inflammatory drugs, medications for
chronic obstructive pulmonary disease (COPD) other
than glucocorticoids, and immunosuppressants (see
online supplementary table S4 for ATC codes).
Patients with anastomotic leakage after colon or rectal
cancer resection
We identified patients with anastomotic leakage
recorded in the Danish Colorectal Cancer Group data-
base or in the Danish National Registry of Patients,
using the ICD codes associated with anastomotic leakage
or surgery codes for surgical repair of anastomotic
leakage (see online supplementary table S5 for ICD-10
codes). Recording of anastomotic leakage in the data-
base is typically based on clinically evident leakage,
which, at the discretion of the surgeon, is confirmed by
contrast barium enema, CT or surgery.
Statistical analysis
We analysed patients with colon and rectal cancer separ-
ately. We tabulated the frequencies of glucocorticoid use
with regard to the characteristics of the patient, the
tumour and the surgery, including p values, by using
Pearson’s χ2 test. According to our predefined gluco-
corticoid exposure groups, we estimated absolute risk of
anastomotic leakage within 30 days postoperatively and
95% CIs using Jeffreys’ method.29 Corresponding risk
differences were calculated subtracting the estimate for
never-use from those for glucocorticoid users. We com-
puted ORs as a measure of relative risk and 95% CIs
associating anastomotic leakage after colon or rectal
cancer surgery with glucocorticoid exposure in crude
and adjusted logistic regression models. On the basis of
their associations with both anastomotic leakage risk and
glucocorticoid use, we included the following covariates
in the model as potential confounders: sex, age, CCI
score, ASA score (≤2, >2, unknown), history of inflam-
matory bowel disease, alcoholism/use of disulfiram
(single variable) and smoking status at the time of the
surgery (current, former, never or unknown), with medi-
cations for COPD as its proxy, as well as prescriptions for
non-aspirin non-steroidal anti-inflammatory drugs filled
within 90 days before the surgery date.30 31 Missing data
(eg, for smoking) were categorised separately and
included in the analysis (see tables 1 and 2 for a descrip-
tion of categories within each covariate). To examine var-
iations in postoperative anastomotic leakage, ORs were
calculated within subgroups of sex, age, year of surgery,
cancer site, cancer stage, CCI score, ASA score and
smoking status, as well as surgical urgency and approach,
type of procedure and perioperative blood transfusion.
In sensitivity analyses, we first changed the time
window for filled glucocorticoid prescriptions to 60 and
120 days before the surgery dates. Second, because there
are no clear standards for the recording of anastomotic
leakage, we restricted anastomotic leakage to patients
who were re-operated on, to heighten the predictive
value of our outcome. Leakages that were treated only
by non-surgical drainage, for example, ultrasonic, were
not included in this analysis.
Statistical analyses were performed using Stata V.12.0
(StataCorp LP, College Station, Texas, USA) and SAS
V.9.2 (SAS Institute Inc, Cary, North Carolina, USA).
RESULTS
Patients with colon cancer
We identified 18 190 patients with colon cancer who had
a primary anastomosis after tumour resection during
Ostenfeld EB, et al. BMJ Open 2015;5:e008045. doi:10.1136/bmjopen-2015-008045 3
Open Access








n (%) p Value
Sex 0.000
Female 7122 (50.7) 2369 (57.1)
Male 6919 (49.3) 1780 (42.9)
Age, years 0.000
<60 2399 (17.1) 482 (11.6)
60–69 3841 (27.4) 949 (22.9)
70–79 4688 (33.4) 1582 (38.1)
80+ 3113 (21.2) 1136 (27.4)
Year of resection 0.000
2001–2004 4767 (34.0) 1074 (25.9)
2005–2008 5327 (37.9) 1642 (39.6)
2009–2011 3947 (28.1) 1433 (34.5)
Stage 0.001
Localised 7192 (51.2) 2261 (54.5)
Non-localised 6510 (46.4) 1785 (43.0)
Unknown 339 (2.4) 103 (2.5)
CCI score 0.001
0 8557 (60.9) 1448 (34.9)
1–2 4074 (29.0) 1812 (43.7)
3+ 1410 (10.0) 889 (21.4)
ASA score 0.000
≤2 10 616 (75.6) 2575 (62.1)
>2 2812 (20.0) 1420 (34.2)
Unknown 613 (4.4) 154 (3.7)
IBD 91 (0.7) 108 (2.6) 0.000
Autoimmune disorders or immunosuppressive drug
use
90 (0.6) 256 (6.2) 0.000
Obesity 405 (2.9) 208 (5.0) 0.000
Alcoholism 488 (3.5) 159 (3.8) 0.276
Tobacco use 0.000
Current use 2088 (14.9) 563 (13.6)
Former use 4159 (29.6) 1429 (34.4)
Never use 3569 (25.4) 898 (21.6)
Unknown 4225 (30.1) 1259 (30.3)
NSAIDs 3337 (23.8) 1180 (28.4) 0.000
COPD medications 1547 (11.0) 2404 (57.9) 0.000
Surgical urgency 0.190
Planned 12 140 (86.5) 3617 (87.2)
Acute 1894 (13.5) 532 (12.8)
Unknown 7 (0.1) 0 (0.0)
Surgical approach 0.004
Laparoscopy 3446 (24.5) 1111 (26.8)
Laparotomy 10 595 (75.5) 3038 (73.2)
Surgical procedure 0.000
Ileocaecal resection 45 (0.3) 8 (0.2)
Right-sided hemicolectomy 6925 (49.3) 2239 (54.0)
Transverse colon resection 356 (2.5) 101 (2.4)
Left-sided hemicolectomy 1546 (11.0) 447 (10.8)
Sigmoid colon resection 4791 (34.1) 1238 (29.8)
Other resections 15 (0.1) 8 (0.2)
Colectomy and IRA 363 (2.6) 108 (2.6)
Rectal resection – –
Perioperative blood transfusion 0.000
Yes 3312 (23.6) 1120 (27.0)
No 10 611 (75.6) 2999 (72.3)
Missing/unknown 118 (0.8) 30 (0.7)
ASA, American Society of Anesthesiologists’ Physical Status Classification; CCI, Charlson Comorbidity Index; COPD, chronic obstructive
pulmonary disease; CRC, colorectal cancer; IBD, inflammatory bowel disease; IRA, ileorectal anastomosis; NSAIDs, non-steroidal
anti-inflammatory drugs.
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2001–2011. We found that 2170 study participants
(11.9%) had at least one prescription for glucocorticoids
within 1 year before their surgery date (table 1).
Glucocorticoid users were more likely than never-users
to be female and elderly (median age 74 vs 71 years).
Compared with never-users, severe comorbidity and a












Female 1737 (40.2) 463 (47.9)
Male 2580 (59.8) 504 (52.1)
Age, years 0.000
<60 1187 (27.5) 224 (23.3)
60–69 1617 (37.5) 321 (33.2)
70–79 1152 (26.7) 326 (33.7)
80+ 361 (8.4) 96 (9.9)
Year of resection 0.004
2001–2004 1418 (32.9) 272 (28.1)
2005–2008 1651 (38.2) 372 (38.5)
2009–2011 1248 (28.9) 323 (33.4)
Stage 0.866
Localised 2460 (57.0) 557 (57.6)
Non-localised 1775 (41.1) 390 (40.3)
Unknown 82 (1.9) 20 (2.1)
CCI score 0.000
0 3131 (72.5) 490 (50.7)
1–2 970 (22.5) 355 (36.7)
3+ 216 (5.0) 122 (12.6)
ASA score 0.000
≤2 3827 (88.3) 766 (79.9)
>2 432 (10.0) 181 (18.7)
Unknown 77 (1.8) 23 (2.4)
IBD 25 (0.6) 6 (0.8) 0.879
Autoimmune disorders or immunosuppressive drug
use
26 (0.6) 50 (5.2) 0.000
Obesity 77 (1.8) 29 (3.0) 0.015
Alcoholism 160 (3.7) 34 (3.5) 0.776
Tobacco use 0.718
Current use 819 (19.0) 182 (18.8)
Former use 1529 (35.4) 359 (37.1)
Never use 1155 (26.8) 244 (25.2)
Unknown 814 (18.9) 182 (18.8)
NSAIDs 806 (18.7) 222 (23.0) 0.002
COPD medications 403 (9.3) 550 (56.9) 0.000
Surgical urgency 0.700
Planned 4295 (99.5) 963 (99.6)
Acute 22 (0.5) 4 (0.4)
Unknown 7 (0.1) 0 (0.0)
Surgical approach 0.141
Laparoscopy 972 (22.5) 239 (24.7)
Laparotomy 3345 (77.5) 728 (75.3)
Surgical procedure
Rectal resection 4317 (100.0) 967 (100.0)
Perioperative blood transfusion 0.907
Yes 830 (19.2) 189 (19.5)
No 3465 (80.3) 774 (80.0)
Missing/unknown 22 (0.5) 4 (0.4)
ASA, American Society of Anesthesiologists’ Physical Status Classification; CCI, Charlson Comorbidity Index; COPD, chronic obstructive
pulmonary disease; CRC, colorectal cancer; IBD, inflammatory bowel disease; NSAIDs, non-steroidal anti-inflammatory drugs.
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high ASA score were almost twice as prevalent among
glucocorticoid users, although 34.9% of users had a CCI
score of 0. Prescriptions for non-steroidal anti-
inflammatory drugs and COPD agents were also more
prevalent among these patients.
Anastomotic leakage occurred in 1184 patients with
colon cancer (6.5%). Glucocorticoid users contributed
287 cases (24.2%), yielding an overall absolute risk of
leakage of 6.9% vs 6.4% among never-users (table 3).
Absolute risk did not differ substantially among sub-
groups of users of oral, inhaled, intestinal-acting or
mixed glucocorticoids.
Compared with never-users, glucocorticoid use overall
was not associated with an increased relative risk of anas-
tomotic leakage (table 3). Although not statistically sig-
nificant, risk was slightly increased among current
(adjusted OR (aOR)=1.24; 95% CI 0.82 to 1.88) and
recent (aOR=1.43; 95% CI 0.87 to 2.34) users of oral
glucocorticoids. The relative risk estimate for use of
intestinal-acting glucocorticoids was imprecise
(aOR=1.47, 95% CI 0.56 to 3.84). We observed no associ-
ation for inhaled glucocorticoids. With the exception of
alcoholism (aOR=2.58; 95% CI 1.23 to 5.39), the associ-
ation between glucocorticoid use and anastomotic
leakage did not differ materially across strata of covari-
ates (figure 2A).
In sensitivity analyses in which the time window for
the definition of current use was changed to 60/
120 days before surgery, results were close to those in
the main analysis, using either cut-off (data not shown).
When we restricted analyses to anastomotic leakages
that required surgical intervention, we observed 98
(8%) fewer outcomes. However, absolute and relative
risk estimates were essentially unchanged (data not
shown).
Rectal cancer patients
Of the 5284 patients with rectal cancer resected, 458
(8.7%) used glucocorticoids within 1 year before
surgery. Among patients with rectal cancer, glucocortic-
oid users were more likely than never-users to be female
and elderly (median age 68 years vs 66 years) (table 2).
Similarly, severe comorbidity, high ASA score and pre-
scriptions of non-steroidal anti-inflammatory drugs and
COPD agents were more prevalent among patients using
glucocorticoids.
Anastomotic leakage occurred in 695 patients with
rectal cancer (13.2%). Overall, the absolute risk of
leakage was 14.6% among glucocorticoid users versus
12.8% among never-users (table 4). Absolute risks
among current, recent and former users of oral gluco-
corticoids were 15.9%, 13.0% and 16.3%, respectively.
Current users of inhaled glucocorticoids had the highest
absolute risk (17.7%); recent users of inhaled glucocorti-
coids and those using mixed glucocorticoids had the
lowest risks (11.1% and 11.7%, respectively).
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Figure 2 (A) Subgroup analysis
associating glucocorticoids and
anastomotic leakage following
colon cancer surgery compared
to never-use. (B) Subgroup
analysis associating
glucocorticoids and anastomotic
leakage following rectal cancer
surgery compared to never-use.
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Compared with never-users, glucocorticoid use was
associated with an increased risk of anastomotic leakage
after rectal cancer resection (aOR=1.36; 95% CI 1.08 to
1.72) (table 4). Relative risks were modestly increased in
all subgroups of oral glucocorticoid users (current use:
aOR=1.28; 95% CI 0.64 to 2.56; recent use: aOR=1.22;
95% CI 0.51 to 2.92; and former use: aOR=1.42; 95% CI
1.00 to 2.01). Among users of inhaled glucocorticoids,
current users had the highest risk: aOR=1.91; 95% CI
1.11 to 3.30. Estimates for the use of intestinal-acting
and mixed glucocorticoids showed no strong associa-
tions. Our stratified analysis revealed no major differ-
ence across strata in the relative association between
glucocorticoid use and postoperative rectal anastomotic
leakage (figure 2B).
After changing the definition of current use to a 60-day
window before surgery, ORs were somewhat higher for
current use of oral glucocorticoids (aOR=1.63; 95% CI
0.77 to 3.46) and somewhat lower for recent users
(aOR=0.97; 95% CI 0.44 to 2.17). However, the 95% CIs
for these estimates overlapped with those of the main
analysis. Remaining estimates were virtually unchanged
using either cut-off (data not shown). When we restricted
analyses to anastomotic leakages that required reopera-
tion, we observed 215 (31%) fewer outcomes. However,
results did not differ materially (data not shown).
DISCUSSION
In this nationwide population-based study, we found that
current and recent users of oral glucocorticoids exhib-
ited a non-significant modest increase in the relative risk
of anastomotic leakage after colon cancer resection.
Among patients with rectal cancer, relative risk increased
moderately for almost any type of glucocorticoid use.
For both cancers, differences in absolute risk among
current and recent users versus never-users were small,
and the clinical impact of their use is therefore limited.
This study extends previous research because it
includes considerably more participants than previous
investigations and provides detailed data on different
types of glucocorticoids and the timing of their use. In
addition, we analysed patients with colon and rectal
cancer separately. Previous studies that examined
whether glucocorticoids predict anastomotic leakage
after CRC resection had inconsistent results.12–18 On the
basis of 12 studies published between 1996 and 2012, a
recent review provided combined rates for leakage: 6.8%
(95% CI 5.5% to 9.1%) in 1034 patients exposed to ster-
oids preoperatively versus 3.3% (95% CI 2.9% to 3.6%)
in 8410 unexposed patients.32 Overall risk was higher in
our cohort of patients with colon and rectal cancer.
Comparison of our findings to previous studies is diffi-
cult because of differences in definitions of exposure,
study populations, indications for resection and surgical
procedures performed. Moreover, the lack of a standard
definition of anastomotic leakage33 is likely to explain
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Other major strengths of the present study include its
population-based design within the setting of a tax-
supported, uniformly organised healthcare system.
Using electronic registries, we had accurate data on
exposure and covariates.25 27 34 The Danish Colorectal
Cancer Group database provided a complete cohort of
patients with CRC during the study period, as well as
detailed information about surgical treatment and anas-
tomotic leakage.22 However, as in all observational
studies of leakage, we cannot entirely exclude the possi-
bility of selection bias. If surgeons are more reluctant to
create a primary anastomosis in glucocorticoid users
than in never-users, patients who receive that procedure
might be a selected group, presumably at lower risk of
leakage. Recording of postoperative complications in the
Danish Colorectal Cancer Group database has been vali-
dated against medical records and demonstrated almost
100% accuracy.35 Nonetheless, because there are no
clear standards for the recording of anastomotic
leakage,33 completeness and validity in the database may
be imperfect. To heighten capture of leakage cases, we
also included those only recorded in the Danish
National Registry of Patients, increasing the number of
cases by 9%. Furthermore, a sensitivity analysis we
restricted to those who required reoperation, to increase
the validity of the outcome, did not greatly change the
observed associations.
Although data in the Danish National Registry of
Medicinal Products are complete,25 some limitations may
exist. The registry includes no detailed information
regarding adherence, and misclassification of non-
adherent patients as users is possible. However,
co-payment requirements and beneficial effects on
serious symptoms increase the likelihood that filled pre-
scriptions reflect actual use. Also, glucocorticoids dis-
pensed during hospitalisation and outpatient clinic visits
are not logged in the Danish National Registry of
Medicinal Products. Nonetheless, stratified analyses
based on discharge diagnoses did not differ materially
from those of the main analysis. Finally, due to a limited
number of individuals in each glucocorticoid category,
we were unable to subcategorise according to dosages of
glucocorticoids. Likewise, the paucity of patients using
intestinal-acting glucocorticoids did not allow for explor-
ing subcategories according to the timing of use.
Misclassification of anastomotic leakage might also
influence our results if glucocorticoid users had a tem-
porary stoma together with their primary anastomosis
more often than never-users. Because a diverting stoma
may reduce the clinical symptoms of leakage, underre-
porting among glucocorticoid users could thus bias the
estimates towards the null.
Glucocorticoid users generally differ from non-users
because of the diseases for which glucocorticoids are
prescribed. This situation may lead to confounding by
indication. Unfortunately, the Danish National Registry
of Medicinal Products provides no data regarding the
indication for glucocorticoids; however, we adjusted for
comorbid conditions and treatments associated with
their use. Unexpectedly, we observed that almost
one-half of the glucocorticoid users had no record of
comorbidity (CCI score=0). However, some of these
patients may have been treated solely by general practi-
tioners whose patients’ files are not logged in the
Danish National Registry of Patients. As a result, record-
ing of CCI conditions from hospitalisations and out-
patient visits may be incomplete. Also, we cannot
exclude the possibility of some uncontrolled confound-
ing by preoperative radiochemotherapy that was not
recorded in the Danish Colorectal Cancer Database
before 2009. However, standard neo-adjuvant treatment
for rectal cancer with long-course radiotherapy and con-
comitant chemotherapy including 5-flourouracil36 has
low emetogenicity and does not commonly imply the
requirement of anti-emetics such as glucocorticoids.
Therefore, preoperative oncological treatment seems
unlikely to explain our findings for rectal cancer.
Although rarely indicated, preoperative chemotherapy
for cancer in the colon may involve glucocorticoids.
However, assuming that chemotherapy may increase risk
of anastomotic leakage after CRC resection, lack of
adjustment for this potential confounding factor would
not explain our null results for colon cancer. Finally,
data regarding smoking were incomplete (27% missing)
and might suffer from under-reporting. Although we
adjusted for smoking and associated diseases/medica-
tions for COPD as proxies, residual confounding may
explain the apparent association between inhaled gluco-
corticoids and anastomotic leakage in patients with
rectal cancer. Given their limited bioavailability, we
would not expect a stronger association for inhaled glu-
cocorticoids than for oral glucocorticoids.37 In conclu-
sion, we found that preadmission glucocorticoid use
increased the risk of anastomotic leakage mainly after
rectal cancer resection. However, differences in absolute
risk were small, and the clinical impact of glucocorticoid
use may therefore be limited.
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